A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
NCT07843485 on ClinicalTrials.gov · last registry update 2026-10-07
Recruiting now, toward 600 participants. Due to report 20 October 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Percentage Change in Body Weight from Baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. petrelintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 2 times since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- petrelintide
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Enrollment
- 600
- Started
- 2026-09-30
- Primary completion
- 2028-10-20 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-07 | Status changed | NOT_YET_RECRUITING → RECRUITING |
| 2026-09-28 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percentage Change in Body Weight from Baseline
Conditions studied
Obesity or Overweight · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the petrelintide page for this molecule’s full trial and approval history.